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Background
The possibility of re-infection is often cited as a reason
for not initiating treatment in injection drug users
(IDUs). Recent observational data suggest that the rate
of re-infection may be reduced following spontaneous
or treatment-induced virologic clearance, although such
data are often retrospective and incomplete.
Purpose of the study
With this in mind, we have undertaken a systematic,
prospective study to evaluate the incidence of HCV vire-
mia in IDUs at risk of new infection.
Methods
We identified a cohort of IDUs receiving care at the
Pender Community Health Centre on Vancouver’s
Downtown East Side. Potential subjects were identified
as either never having been infected with HCV (non-
infected arm), having spontaneously cleared the virus
(spontaneous arm), or having achieved a sustained viro-
logic response on antiviral treatment (SVR arm). A
questionnaire to identify demographics, health status,
risk behavior and drug use was administered at baseline
and every 6 months, along with blood tests to identify
their HCV status.
Results
A total of 73 subjects met criteria for inclusion in the
study: 20 in the non-infected, 30 in the spontaneous and
23 in the SVR arms respectively. Their mean age was
44.7, 17 were female, 9 were HIV-positive. There were no
significant differences among the 3 groups with respect
to age, ethnicity, source of income, unstable housing and
being on opiate maintenance program. Over a mean fol-
low-up period of 10.3 months, 20% of the non-infected
group became viremic, as compared to 0% of the other
two groups (p=0.04). Injecting drugs in past 30 days
(p=0.05), heroin (p=0.015), amphetamines (p=0.05), and
combined drugs use (p=0.001) were significantly higher
in the non-infected arm compared to SVR arm. There
were no significant differences in drug use and risk beha-
vior between non-infected and spontaneous arms.
Conclusions
Our study shows that viremic HCV infection is more likely
to occur in those who have never been previously infected,
and that this susceptibility to infection cannot be comple-
tely explained by an increase in risk behavior, at least as
compared to individuals who have cleared their viremia
spontaneously. In addition, HIV co-infection is not a sig-
nificant factor associated with recurrent HCV viremia.
Whether a decreased rate of viremia following SVR relates
to some host-related protective factors or is due to a
change in IDU-related risk as a result of engagement in
the health care system is currently under study.
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